Long-Term Utilization Differences Between Children Treated with Clobazam vs. Clonazepam for Epilepsy in the UK (P1.261)

OBJECTIVE: To compare the clinical utilization of clobazam (CLB) and clonazepam (CLN), data were evaluated for patients u003c18 years receiving CLB vs. CLN for epilepsy. BACKGROUND: Both CLB and CLN have been used for years in Europe for many disorders. Long-term comparisons have not been conducted, particularly for children. The Clinical Practice Research Datalink (CPRD) database, a large, longitudinal database, consists of electronic medical records from general practitioners located throughout the UK DESIGN/METHODS: with 蠅1 incident prescription of CLB or CLN from 1995-2011 were included. Index date was a patient’s first prescription date. Patients must have been in the database 蠅182 days before the index date with no prescriptions for CLB or Results for subgroups of children diagnosed with epilepsy before the index date or ≤90 days after were evaluated. RESULTS: Of 21,099 patients meeting inclusion criteria, 3,882 received CLB, and 17,217 CLB use has been predominantly in epilepsy (76.1[percnt]), while CLN use in epilepsy was 8.7[percnt]. Patients u003c18 years included 574 receiving CLB and 171 receiving percentages of patients treated with CLB (92[percnt]) vs. CLN (89[percnt]) were receiving concomitant AEDs, and similar percentages (91[percnt] vs. 90[percnt]) were benzodiazepine-naive at baseline. CLN patients had a statistically longer follow-up period vs. CLB patients (6.3 vs. 5.5 years, p=0.03). Median CLB dosage did not increase from baseline (20.0 mg), while median CLN dosage increased 50[percnt] (1.0 mg to 1.5 mg). CONCLUSIONS: Similar percentages of children with epilepsy treated with CLB and CLN were receiving concomitant AEDs. CLB dosage appeared to remain stable over time, while CLN dosage appeared to increase from baseline, possibly a result of pharmaco-tolerance from long-term use of CLN. Study Supported by: LLC Disclosure: Dr. Chung has received personal compensation for activities with UCB Pharma, Supermus, Esai Inc., Lundbeck Research USA, Inc., Upshire-Smith, and SK Life Science. Dr. Brodie has received personal compensation for activities with Eisai Inc., UCB Pharma, GlaxoSmithKline, Takeda Pharmaceutical Company, GW Pharmaceuticals, and Bial as advisory board member and/or speaker. Dr. Wade has received personal compensation for activities with Lundbeck Research USA, Inc. as a consultant. Dr. Quelen has received personal compensation for activities with Lundbeck Research USA, Inc. as an employee. Dr. Guiraud-Diawara has received personal compensation for activities with Lundbeck Research USA, Inc. as an employee. Dr. Francois has received personal compensation for activities with Lundbeck Research USA, Inc. Dr. Francois holds stock and/or stock options in Lundbeck Research USA, Inc. Dr. Verpillat has received personal compensation for activities with Lundbeck Research USA, Inc. as an employee. Dr. Shen has received personal compensation for activities with Lundbeck Research USA, Inc. as an employee. Dr. Jones has received personal compensation for activities with Lundbeck Research USA, Inc. and Biogen Idec as an employee. Dr. Isojarvi has received personal compensation for activities with Lundbeck Research USA, Inc. as an employee.